The theme of last week was big strategic repositioning and direct category combat.
J&J reported Q3 ortho growth of 3.4% ($2.34B), but the real headliner came from CFO Joseph Wolk, who signaled J&J is “leaning towards a spin” of DePuy Synthes by mid-2027. That puts a real structural timeline on the Apollo headlines we’ve been tracking. Stryker didn't wait around—it dropped ~$400M into CMR Surgical for exclusive U.S. commercial rights to the Versius soft-tissue robot, plus an option to buy the whole company, carving out a huge soft-tissue and ASC runway alongside Mako.
In spine, NASS in San Antonio was the main stage. Carlsmed fully launched its patient-specific aprevo posterior system, and Globus Medical fired back immediately, showcasing its FDA-cleared SCRIPT patient-specific platform that maps straight into ExcelsiusGPS. The patient-specific interbody arms race is officially here. Meanwhile, Centinel Spine picked up a two-level FDA nod for prodisc C Nova while we keep waiting on the IPO pricing.
Sector
Notable Move
Key Strategic Implication
Large-Cap / Spin Watch
J&J Q3 ortho +3.4% ($2.34B); CFO signals "leaning towards a spin" of DePuy Synthes by mid-2027
The...
